X0508 4 2025-01-31 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001661887 Grund Nicholas C/O AKEBIA THERAPEUTICS, INC 245 FIRST ST. CAMBRIDGE MA 02142 false true false false Chief Commercial Officer true Common Stock 2025-01-31 4 A false 194900.00 0.00 A 498200.00 D Common Stock 2025-02-03 4 S false 55621.00 2.10 D 442579.00 D Stock Option (Right to buy) 2.24 2025-01-31 4 A false 292300.00 0.00 A 2035-01-31 Common Stock 292300.00 292300.00 D The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2024. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. /s/Carolyn Rucci, attorney-in-fact for Nicholas Grund 2025-02-04